Patents by Inventor Ouathek Ouerfelli

Ouathek Ouerfelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200115361
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10556882
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10526310
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 7, 2020
    Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20190330182
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 31, 2019
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20190241539
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10308630
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignees: Sloan-Kettering Institute for Cancer Research, Aragon Pharmaceuticals, Inc.
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Publication number: 20180258067
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: Anna DILHAS, Mark R. HERBERT, Ouathek OUERFELLI, Nicholas D. Smith
  • Publication number: 20180237407
    Abstract: Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Applicants: Memorial Sloan-Kettering Cancer Center, Albert Einstein College of Medicine, Inc.
    Inventors: Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang, Evripidis Gavathiotis
  • Publication number: 20180237406
    Abstract: Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang
  • Patent number: 9994545
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 12, 2018
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 9943507
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 17, 2018
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Patent number: 9926291
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: March 27, 2018
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • Publication number: 20170252328
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Application
    Filed: March 15, 2017
    Publication date: September 7, 2017
    Applicants: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Publication number: 20170081308
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • Patent number: 9597320
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 21, 2017
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Patent number: 9546146
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 17, 2017
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcolm Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
  • Publication number: 20170001977
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Application
    Filed: September 12, 2016
    Publication date: January 5, 2017
    Inventors: ANNA DILHAS, MARK R. HERBERT, OUATHEK OUERFELLI, NICHOLAS D. SMITH
  • Patent number: 9512103
    Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: December 6, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
  • Patent number: 9481663
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: November 1, 2016
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research
    Inventors: Anna Dilhas, Mark R Herbert, Ouathek Ouerfelli, Nicholas D Smith
  • Publication number: 20160221984
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 9, 2016
    Publication date: August 4, 2016
    Inventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcolm Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang